RASpecting the oncogene: New pathways to therapeutic advances

[Display omitted] RAS is the most commonly mutated driver of tumorigenesis, seen in about 30% of all cancer cases. There is a subset of tumors termed RAS-driven cancers in which RAS mutation or overactivation is evident, including as much as 95% in pancreatic and 50% in colon cancer. RAS is a family...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Biochemical pharmacology 2018-12, Vol.158, p.217-228
Hauptverfasser:	Stout, Matthew C., Campbell, Paul M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Cancer Drug discovery RAS Signaling Therapeutics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!